Canadians Overwhelmingly Support Legal Access to Psilocybin-Assisted Therapy, Poll Reveals
Psilocybin Alpha, August 4, 2021
A new poll, commissioned by the Canadian Psychedelic Association, has highlighted widespread support for legal access to psilocybin-assisted therapy among Canadians.
New Yale Study Shows Psilocybin Spurs Growth of Neural Connections Lost in Depression
Microdose.buzz, August 3, 2021
A new study conducted by researchers at Yale University showed psilocybin can facilitate the regrowth of neurons lost in depression.
Just One Dose of Magic Mushroom Compound Regrows Lost Brain Connections in Mice
Science Alert, July 6, 2021
Psilocybin, the active psychedelic compound, has some curious effects on the human brain.
Psychedelic IPOs build momentum as Atai Life Sciences goes public
PitchBook, June 18, 2021
Making its Wall Street debut, Peter Thiel-backed Atai Life Sciences has become the third biotech company focused on psychedelic treatment for mental health disorders to list on a major US stock exchange.
My team’s research shows magic mushrooms treat depression, but undoing the stigma will be a bigger challenge
iNews, June 3, 2021
Bringing psychedelic therapy into mainstream treatment will present some major challenges.
Magic mushroom microdosing: Sick Kiwis call for ‘life-saving’ Class-A drug to be legalised
Newshub, May 29, 2021
Every day Kiwis with devastating illnesses are turning to small doses of psychedelics to find relief and are calling for what they call a ‘life-saving’ treatment to be made legal for medical purposes.
Ketamine a game changer in treating eating disorders
Toronto Sun, May 29, 2021
Ketamine, MDMA and psilocybin are proving useful with treatment-resistant mental illnesses, including eating disorders.
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
Globe News Wire, May 27, 2021
Algernon recently established a clinical research program for the treatment of stroke focused on DMT.
Could the ‘spirit molecule’ be a treatment option for stroke?
Vancouver Sun, May 25, 2021
Researchers have spent decades and billions of dollars unsuccessfully searching for novel treatments for stroke. Now a Vancouver-based company is putting a unique hypothesis to the test.
Psychedelic medicine is about to blow up
Fast Company, May 11, 2021
New clinical data shows that MDMA-assisted therapy can have a significant impact on PTSD, paving the way for FDA approval and commercialization.
Who’s in Charge of Psilocybin?
Chacruna, May 10, 2021
From clinicians and investors to Indigenous groups and activists, debate is raging over whether psychedelics are spiritual tools, new psychiatric drugs, medicines for social change, or all of the above.
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
The New York Times, May 9, 2021
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Legalise ‘magic mushrooms’ to help cure depression, says London scientist
My London, May 6, 2021
The director of a pioneering psychedelic research centre on the benefits and limitations of psychedelics for depression.
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD
MAPS, May 3, 2021
The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
A Psychedelic Drug Passes a Big Test for PTSD Treatment
The New York Times, May 3, 2021
A new study shows that MDMA can bring relief when paired with talk therapy to those with severe post-traumatic stress disorder.
There Is a Lot of Fungus Among Us
The New York Times, April 24, 2021
Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.
Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics
The Crimson, April 23, 2021
Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.
Psychedelics are transforming the way we understand depression and its treatment
The Guardian, April 20, 2021
Psychiatry has long failed to explain depression. Our research into psilocybin suggests a new approach could offer answers.
Psilocybin least as good as antidepressant in UK study
Reuters, April 15, 2021
A study published in the New England Journal of Medicine, psilocybin could be as effective as a leading antidepressant—and while more research is still required, the study’s lead author says the results should give people hope for functional alternatives to SSRIs.
New $6.4M research program to advance psychedelics research and treatments
Eurek Alert, March 30, 2021
Psychedelics research in support of brain health is getting a major boost this month with the formation of the Neuroscape Psychedelics Division at the University of California, San Francisco (UCSF).